APAC Infectious Disease Therapeutics Market

APAC Infectious Disease Therapeutics Market Size (2024 to 2029)

The size of the Asia-Pacific Infectious Disease Therapeutics Market was worth USD 20.02 Billion in 2024. It is further estimated to grow and be worth USD  31.18  Billion by the end of 2029, growing at a CAGR of 9.27% between 2024 to 2029. Asia-Pacific is expected to account for the second-largest share in the market due to the increasing pool of patients and government funding.

Infectious diseases such as HIV, malaria, tuberculosis, hepatitis A, B, C, and influenza are among the most severe threats to public health in the Asia Pacific. In the Asia-Pacific, infectious diseases are the leading cause of death. According to the World Health Organization (WHO), infectious diseases are responsible for 16% of worldwide deaths.

Y-O-Y rise in the prevalence of infectious diseases, technological developments, and more government financing and investments are a few of the key factors accelerating the growth rate of the infectious disease therapeutics market in the APAC region. In the worldwide infectious diseases treatments market, Asia Pacific is predicted to rise at the fastest growth rate during the forecast period. The enormous pool of patients and increased government financing are two significant driving reasons for emerging countries' infectious diseases treatments industry. In addition, growing usage of infectious diseases therapeutics, increased use of direct-acting antivirals, increasing elderly population, and rising healthcare expenditure are key drivers driving the growth of the Asia-Pacific infectious diseases therapeutics market.

More significant investments to enhance the penetration rate of infectious illness treatments, higher initiatives to raise knowledge about treatments and diagnosis, and increased clinical trial studies for developing new pharmaceuticals are further predicted to move this market forward during the forecast period.

However, factors that are expected to hinder the market growth of infectious disease therapies in the Asia Pacific, including a lack of advanced healthcare facilities in underdeveloped countries, which is expected to have a downward trend in the market growth over the projected timeframe. In addition, the high cost of hospitalization, restrictions on senior people accessing modern therapies, a lack of public understanding of new treatment methods, and social isolation in public gatherings are all barriers to market growth.

This research report on the Asia Pacific infectious disease therapeutics market has been segmented & sub-segmented into the following categories:

APAC Infectious Disease Therapeutics Market Analysis By Mode of Treatment

• Drugs     
• Vaccines    

APAC Infectious Disease Therapeutics Market Analysis By Target Organism:

• Antibacterial      
• Antifungal
• Antiviral  
• Antiparasite      
• others     

APAC Infectious Disease Therapeutics Market Analysis By Infection Type

• Bacterial  
• Viral      
• Fungal    
• Parasitic  
• Others    

APAC Infectious Disease Therapeutics Market Analysis By Distribution Channels

• Hospitals  
• Clinics     
• Others

By Country

• India
• China
• Japan
• South Korea
• Australia
• New Zealand
• Thailand
• Malaysia
• Vietnam
• Philippines
• Indonesia
• Singapore
• Rest of APAC

Geographically, the Asia-Pacific region is one of the most rapidly developing. Infectious disease drugs are expected to be in high demand in the region due to the increased prevalence of such conditions and a favorable reimbursement environment. Furthermore, China and India have a significant number of producers and an increasing number of clinical trials for the development of novel therapeutic drugs, which are expected to add to the region's large market.  The growing prevalence of infectious disease treatment and diagnostics and increased funding initiatives to assist the development of innovative drugs are expected to propel this business forward.

The high prevalence of HIV, malaria, tuberculosis and other infections in China and India, the rising incidence of these diseases, and rising expenditure on infectious disease prevention and diagnostics are expected to drive the regional market's growth. Moreover, throughout the forecast period, governments of various countries are expected to increase their attention on infection prevention and generate funds to support the adoption of therapies for infectious diseases, driving the market even further.

KEY MARKET PLAYERS

Companies playing a significant role in the APAC Infectious disease Therapeutics Market profiled in this report are F. Hoffmann-La Roche, Gilead Sciences, GlaxoSmithKline, Johnson & Johnson, Merck & Co, Pfizer, Achillion Pharmaceuticals, Novartis, AbbVie, Astellas Pharma, AstraZeneca, Auritec Pharmaceuticals, Bayer, Bristol-Myers Squibb, Chimerix Pharmaceuticals, Cubist, Eli Lilly, Isis Pharmaceuticals, Mitsubishi Tanabe Pharma, pSivida and Sanofi.